Welcome to our dedicated page for Kenvue news (Ticker: KVUE), a resource for investors and traders seeking the latest updates and insights on Kenvue stock.
Kenvue Inc. (NYSE: KVUE) is recognized as the world's largest pure-play consumer health company, boasting an impressive annual revenue of $15 billion. Established as an independent entity in May 2023 after its spin-off from Johnson & Johnson's consumer segment, Kenvue has rapidly distinguished itself in the market. The company's diverse portfolio spans across several key sectors within the consumer health industry, including cough, cold, and allergy care, pain management, face and body care, oral care, and women's health.
Some of the most iconic brands under Kenvue's umbrella include Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. These brands hold significant market positions globally, attributed to their strong brand equity and consumer trust. Despite operating in a highly fragmented and competitive industry, Kenvue's commitment to quality and innovation has kept it ahead of the curve.
Recently, Kenvue has made strides in its environmental, social, and governance (ESG) initiatives. In May 2024, the Science Based Targets initiative (SBTi) validated Kenvue's near-term greenhouse gas (GHG) emissions reduction targets, aligning with the goal to limit global temperature rise to 1.5°C. This validation underscores Kenvue's dedication to sustainability and its mission to advance the well-being of both people and the planet through its Healthy Lives Mission.
Financially, Kenvue maintains a robust position with a clear focus on expanding its product lines and market reach. The company continues to invest in research and development to enhance its product offerings. Strategic partnerships and collaborations are also central to Kenvue's growth strategy, further solidifying its presence in the consumer health sector.
For the latest updates and information on Kenvue's performance, current projects, and recent achievements, investors and stakeholders are encouraged to visit the company's official website and review its filings with the Securities and Exchange Commission.
Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company by revenue, has announced its participation in the upcoming Consumer Analyst Group of New York (CAGNY) Conference. The presentation will take place on Wednesday, February 19, 2025, at 3:00 p.m. Eastern Time.
Key executives participating include Thibaut Mongon (CEO), Paul Ruh (CFO), and Charmaine England (Chief Growth Officer). The presentation will be accessible via live webcast on investors.kenvue.com, with a replay available afterward.
Kenvue's portfolio includes renowned brands such as Aveeno®, BAND-AID®, Johnson's®, Listerine®, Neutrogena®, and Tylenol®. These science-backed products are globally recommended by healthcare professionals and build on more than a century of heritage in everyday care.
Kenvue (KVUE) reported mixed results for Q4 and full year 2024. Q4 net sales slightly decreased by 0.1% to $3.7 billion, while organic sales grew 1.7%. Full-year net sales increased 0.1% to $15.5 billion with organic growth of 1.5%.
Q4 diluted EPS was $0.15 (vs $0.17 prior year) and adjusted diluted EPS was $0.26 (vs $0.31). Full-year 2024 diluted EPS reached $0.54 (vs $0.90) and adjusted diluted EPS was $1.14 (vs $1.29).
The company's 2024 gross profit margin improved by 200 basis points, supported by Vue Forward savings and increased marketing investments. For 2025, Kenvue expects net sales change between -1% to +1%, organic sales growth of 2-4%, and flat to +2% adjusted diluted EPS growth, with consideration for a ~3% foreign currency headwind.
Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company by revenue, has responded to Starboard Value's submission of four director nominees for election to Kenvue's Board at the 2025 Annual Meeting of Shareholders. The company emphasized its commitment to shareholder value and ongoing engagement with shareholders, noting previous discussions between Kenvue's Board and Starboard.
The company highlighted its focus on portfolio optimization through increased marketing investments supported by cost savings initiatives. Kenvue's Board currently consists of 11 highly qualified directors with executive leadership experience in consumer, retail, and healthcare companies. Recently, two Johnson & Johnson executives resigned from the Board and were replaced by two new independent directors.
The Board is currently reviewing Starboard's proposed candidates and will provide its formal recommendation in due course.
Kenvue Inc. (NYSE: KVUE) has announced global artist Tate McRae as Neutrogena's newest global brand ambassador, launching the brand's new 'Beauty to a Science' positioning. The announcement coincides with the 10th anniversary of Neutrogena's Hydro Boost collection, which sells one Water Gel jar every two seconds worldwide.
The campaign features McRae alongside Neutrogena Global Innovation Partner Dr. Muneeb Shah, focusing on how stress affects skin health. McRae, 21, will be featured across multiple marketing platforms, including TV, social media, digital, and point of sale, while integrating the brand into her future projects.
The partnership emphasizes Hydro Boost's weightless formula and hyaluronic acid technology, marking a significant milestone for the product line that helped establish the hyaluronic acid category in skincare.
Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company, has scheduled its fourth quarter and full year 2024 financial results announcement for February 6, 2025, before market open. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results.
Investors can access the conference call by dialing 877-407-8835 (U.S.) or +1 201-689-8779 (international). A live webcast will be available at investors.kenvue.com, with a replay accessible after the event. Kenvue's portfolio includes well-known brands such as Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol.
Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company, has announced a quarterly dividend of $0.205 per share on its common stock. The dividend will be payable on February 26, 2025, to shareholders of record as of the close of business on February 12, 2025.
The company is known for its iconic consumer health brands including Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol. These brands are science-backed and recommended by healthcare professionals globally.
Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company, announced its participation in the Morgan Stanley Global Consumer & Retail Conference in New York City. CEO Thibaut Mongon and CFO Paul Ruh will engage in a fireside chat on Wednesday, December 4, 2024, at 11:45 a.m. Eastern Time. The event will be accessible via live webcast on investors.kenvue.com, with a replay available afterward. Kenvue's portfolio includes well-known brands such as Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol.
Kenvue (KVUE) reported Q3 2024 financial results with net sales decreasing 0.4% to $3.9 billion, while organic growth was 0.9%. The quarter saw a 2.5% value realization from pricing and mix, offset by a 1.6% volume decline. Gross profit margin expanded 100 basis points to 58.5%, while adjusted gross profit margin increased 130 basis points to 60.7%. Diluted EPS was $0.20, down from $0.23, and adjusted diluted EPS was $0.28, compared to $0.31 in the prior year. The company expects 2024 net sales growth and organic growth toward the low end of 1.0%-3.0% and 2.0%-4.0% respectively.
Neutrogena®, part of Kenvue Inc. (NYSE: KVUE), announced multi-year partnerships with dermatologists Dr. Dhaval Bhanusali and Dr. Muneeb Shah to enhance its dermatological beauty offerings. As Global Innovation Partners, they will focus on three key areas: innovation acceleration, consumer engagement, and dermatologist collaboration. The partnership aims to advance clinical science, improve product experience, and build consumer community engagement. This initiative reinforces Neutrogena's position as America's #1 facial skincare brand and strengthens its commitment to combining beauty with scientific innovation.
Starboard Value LP, an investment adviser, announced that its CEO Jeffrey Smith presented at the 2024 Active-Passive Investor Summit. The presentation highlighted value creation opportunities at three companies: Kenvue Inc. (NYSE: KVUE), Pfizer Inc. (NYSE: PFE), and Salesforce Inc. (NYSE: CRM).
The full presentation and individual company presentations are available on Starboard's website. Starboard Value LP focuses on investing in deeply undervalued companies and actively engages with management teams and boards to unlock shareholder value.
FAQ
What is the current stock price of Kenvue (KVUE)?
What is the market cap of Kenvue (KVUE)?
What is Kenvue Inc.?
When did Kenvue go public?
What are some of Kenvue's well-known brands?
What sectors does Kenvue operate in?
What recent achievements has Kenvue made?
What is Kenvue's Healthy Lives Mission?
How does Kenvue approach ESG initiatives?
What is the financial condition of Kenvue?
How can I find more information about Kenvue's financial performance?
Who can I contact for investor relations at Kenvue?
